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conducted in the 1980s, is estimated 
to run to £15 billion. 
The UK government’s Sustainable 
Development Commission (SDC) 
estimates that this facility could save 
5.6 Mt carbon dioxide per year, in 
comparison to new-built gas-fired 
power plants. The carbon footprint of 
building the barrage would be paid 
back in 5–8 months, according to the 
SDC. The concept is based on proven 
technology, as a similar barrage at the 
river Rance, in Northern France, has 
operated successfully since 1966.
Even though this would clearly be 
a significant measure to avoid carbon 
emissions, environmentalists are up 
in arms against the idea of a Cardiff–
Weston barrage. It would ensure that 
large areas that are currently tidal 
marshland would be permanently 
under water, and the government 
admits that “some of the biodiversity 
would be lost.” For this reason, the 
Royal Society for the Protection 
of Birds (RSPB) has criticised the 
decision to include the large barrage 
in the shortlist. 
The Severn estuary, which 
divides England from southern 
Wales, has the second largest 
tidal range in the world, so it 
seems a natural target to try 
to harvest tidal energy there, 
in one of the biggest potential 
projects to exploit renewable 
energy
Alternative barrage projects could 
be located further up the river delta, 
with proportionally smaller impact on 
the environment and building cost, 
but also smaller energy generation 
and carbon dioxide savings. Two 
such barrage projects are under 
consideration, generating 1 GW and 
0.625 GW, respectively. 
Leaving much of the estuary  
open to the tides, a small barrage 
could be combined with a ‘tidal 
lagoon’ — a walled-off area of  
water that is connected only to one  
side of the river delta and thus 
doesn’t block it off. Two such lagoons 
are on the shortlist, each estimated 
to generate 1.36 GW. These would 
still sacrifice some marshland, but 
would leave the majority of it intact. 
Because of the semicircular geometry 
of the wall that needs to be built 
around a given volume of water to 
harvest its flow, these lagoons may 
turn out to be more expensive to 
build than barrages of comparable 
energy output. 
Other options left off the 
government shortlist but favoured 
by some environmentalists include 
offshore tidal lagoons and tidal 
flow turbines. The environmental 
organisation Friends of the Earth (FoE) 
has presented a study comparing tidal 
lagoons with barrage projects. While 
offshore lagoons would require more 
building material per water volume 
reigned in, the fact that they are not 
connected to rivers or shores would 
allow the operators to use the tidal 
range to the maximum and in both 
directions. While a barrage would 
only generate hydroelectric power 
from the water running out to the sea, 
an enclosed tidal lagoon could be 
allowed to run completely empty at 
ebb tide, and thus also to generate 
electricity while it is refilled with the 
incoming tide. Based on this two-way 
mechanism, the FoE study estimates 
that electricity from a lagoon would 
end up being more economical than 
from a barrage. 
Upon publication of the 
government shortlist, FoE voiced 
strong criticism of the decision 
not to include offshore lagoons. 
Gordon James, the director of the 
Welsh branch of FoE, said: “The 
development of tidal lagoons would 
have delivered huge quantities of 
green power more cheaply and 
quickly than a barrage, and with less 
impact on the environment.”
The government is now conducting 
the second phase of its feasibility 
study, which will look at the technical 
details and environmental concerns 
connected to the shortlisted projects 
and will lead towards a full public 
consultation in early 2010. If a large 
barrage project is approved at that 
point, design and construction 
work could take up to 12 years to 
complete. 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.uk
Links:
Government: http://www.berr.gov.uk/
energy/severntidalpower
FoE: http://www.foe.co.uk/resource/
briefings/severn_barrage_lagoons.pdfThe chief executive of the world’s 
second largest pharmaceutical 
company, GlaxoSmithKline, has 
pledged to relax its grip on its 
intellectual property concerning 
potentially useful patents for the 
development of new therapies for 
treating tropical diseases, as the new 
European Union trade commissioner 
pushes ahead for ever stronger global 
protection for such property.
Andrew Witty, the GSK chief 
executive, announced a plan last 
month with four components. The 
key is to set up a patent pool for 
medicines for neglected tropical 
diseases in which GSK would put its 
small molecule compounds or process 
patents to allow free access to anyone 
wanting to develop medicines and 
products.
The key is to set up a patent 
pool for medicines for 
 neglected tropical diseases
The aim is to speed up the 
development of new drugs for Third 
World diseases such as TB and 
malaria. However, Witty has ruled 
out access to patents for HIV/Aids 
medicines because he says there is 
already enough innovation in this area.
The other offer from Witty is the 
plan to sell medicines cheaply to the 
least-developed countries. Prices will 
be cut to a quarter of the rates GSK 
charges in the US and UK — and even 
less if possible. Along with this is a 
promise to reinvest 20 per cent of any 
profits it makes in these countries into 
their own hospitals, clinics and staff. 
In addition, drugs would be made 
more affordable in middle-income 
countries such as Brazil and India.
He also said GSK will invite 
scientists from other companies, 
NGOs or governments to join the 
hunt for tropical disease treatments 
at its dedicated institute at Tres 
Cantos, Spain. Witty, talking to The 
Guardian, said that his stance “may 
GlaxoSmithKline wants to share 
patents and improve drug access in 
developing countries. Nigel Williams 
reports.
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Have you always been interested 
in biology? I can’t remember a time 
when I wasn’t interested in biology, 
particularly animal behavior and 
evolution. My family lived in rural 
Ohio when I was four or five years 
old, and I recall spending a lot of time 
outdoors watching hummingbirds 
around the big spruce trees next to 
our house. A more formative moment 
was when my mother took me to 
the Cleveland Museum of Natural 
History and I had the chance to see 
the ‘Lucy’ skeleton (Australopithecus 
afarensis) — at that time the earliest 
known hominid specimen. This was 
a truly transformative experience, 
and generated an intense obsession 
with primate and human evolution, 
altogether at odds with my strict 
Catholic upbringing. Throughout 
childhood, I kept a set of Time-Life 
books on ‘Evolution’, ‘The Primates’, 
and ‘Animal Behavior’ under my bed 
to read each night before going to 
Q & Aoperates in a number of them and earns there only around £30 million.
Despite the concerns, many still 
believe Witty’s pledge marks a major 
step forward for neglected diseases 
and developing countries. “He is 
breaking the mould in validating 
the concept of patent pools,” said 
Rohit Malpani at Oxfam’s access to 
medicines campaign. “It is a big step 
forward. It is welcome that he is inviting 
other companies to take this on.”
But positive moves in the 
development of medicines by 
freeing up patents by GSK in certain 
areas is not a signal for a wider 
loosening on intellectual property. If 
anything, Europe is getting tougher in 
protecting its patents. The EU’s trade 
commissioner, Catherine Ashton, 
is currently pushing developing 
countries to accept stringent 
provisions on intellectual property. 
This goal “prioritises the rights of 
patent holders at the expense of 
access to medicines, jeopardising 
health in developing countries,” writes 
Monika Kosininska, secretary-general 
of the European Public Health Alliance 
in a letter to The Guardian. 
“The European Commission has 
made commitments in multilateral 
fora, such as the WHO and the WTO’s 
2001 Doha declaration, to support 
health in developing countries. The 
behaviour of Ashton undermines these 
commitments,” she says.
not win him many friends in the other 
drug companies,” but he hoped they 
would join him in an effort to make a 
significant difference to the health of 
people in poor countries.
Médecins Sans Frontières, a leading 
health NGO, says Witty’s price cut for 
drugs is welcome but not a panacea 
for availability of drugs. And the 
charity is also disappointed that HIV/
Aids patents have not been included 
in the proposed patent pool.
The charity World Vision’s director 
of advocacy, Mike French, said: 
“Slashing drug prices is good. 
But, without the necessary health 
infrastructure, many won’t be able 
to access those drugs. Therefore, 
investment by GSK, along with the 
knowledge pooling, makes this a 
landmark announcement.”
Drug companies are criticised for 
failing to deliver for the rich world 
as well as the poor. They are often 
accused of focusing their efforts on 
making barely altered copies of other 
companies’ billion-dollar sellers rather 
than working on diseases where 
there are few treatments, such as 
Alzheimer’s.
Critics of the drug companies 
acknowledged that in these moves 
GSK was making major strides but 
said that it could go further: promising 
20 per cent of profits from sales in the 
least developed countries does not 
amount to a huge sum as GSK only 
Shifting: Andrew Witty, chief executive of the pharmaceutical company GSK last month an-
nounced a range of measures to try to improve drug development and availability in developing 
countries. (Photo: GSK.)
